Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.
about
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupNeuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated EntitiesProgressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumaratePML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.Brain Biopsy Is More Reliable than the DNA test for JC Virus in Cerebrospinal Fluid for the Diagnosis of Progressive Multifocal Leukoencephalopathy.Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromesCerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathyPathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case studyBroadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathyDiagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathyProgressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod.A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.Medications and therapeutic apheresis procedures: are we doing our best?The human JC polyomavirus (JCPyV): virological background and clinical implications.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Natalizumab in relapsing-remitting multiple sclerosis.Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?Sequential changes in the non-coding control region sequences of JC polyomaviruses from the cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy.A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab.Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem.Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
P2860
Q26780412-03EDFF07-757F-4D2E-B378-09BCD79B00BBQ26781389-3759A238-7D6C-409E-95A7-89DC21EB1055Q28083338-2636383C-CB32-4AB5-B558-57A495432C30Q30613846-089286C6-F122-4D03-B962-6783AD8F4D99Q30815289-678263A3-A4C8-49D9-883B-EF7FA5D20357Q32182100-3F1E9164-B620-45D3-99FA-0E5A135820EEQ33573208-3F563602-82F5-4DC7-A32B-B48A26A55194Q33814485-3A62B5C3-9DC4-41DA-946D-7DE6C59ED295Q34324861-41857E06-4184-42E2-A948-67C8515D3C15Q35675602-8610801A-BBFD-43F3-8FF8-AD18A4561658Q35736438-2AE73BC6-0B70-47BE-BE05-42951FD62537Q36242324-928D8D61-C895-4990-8913-07C93F18E518Q36764988-9AFAB085-FC74-44D6-BFCA-E7611975D750Q36942417-31859F12-A16E-4A8F-8845-619E1B53E695Q37475542-E197E458-EF5E-4FA1-991B-98DB6C1B4B32Q38068499-63117AAE-9D6C-4DEF-8E6A-E5140D208891Q38082738-FD12C0A1-5F6B-4F79-A08C-05AD9CA44B4EQ38115572-BC075109-2B07-4DD2-9016-57BFB4574B7EQ38172961-73E81D98-5698-4AE3-9D28-2AAD58493250Q38786252-FB47453F-BA74-480E-B34B-42B240BA8832Q39525743-1C215146-7918-4BDC-B395-9A024F270F89Q42226607-02849130-2516-4BE4-B8AC-77A99FA877C1Q42287198-C005879A-FCC7-4862-9132-7052EA9E1BD3Q44260772-C864F8AD-B380-4B64-8DD9-370867627575Q48208073-BD7723F0-1885-4F1F-9EF5-474DBAF880BFQ48846624-C6EED229-842A-42CD-87D5-32CAF6B9B8B9Q50858454-2BBA7E10-840D-47F8-ADA4-40FFAC7C31CDQ52659119-C11AF839-91F6-4D4A-B652-80ACC80BDD04
P2860
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Management and outcome of CSF- ...... zumab-treated patient with MS.
@ast
Management and outcome of CSF- ...... zumab-treated patient with MS.
@en
type
label
Management and outcome of CSF- ...... zumab-treated patient with MS.
@ast
Management and outcome of CSF- ...... zumab-treated patient with MS.
@en
prefLabel
Management and outcome of CSF- ...... zumab-treated patient with MS.
@ast
Management and outcome of CSF- ...... zumab-treated patient with MS.
@en
P2093
P2860
P1433
P1476
Management and outcome of CSF- ...... zumab-treated patient with MS.
@en
P2093
C Ryschkewitsch
H H Hirsch
O Yaldizli
P2860
P304
P356
10.1212/WNL.0B013E31823B9B27
P407
P577
2011-11-09T00:00:00Z